Recursion Pharmaceuticals, Inc. (RXRX): who owns it and who trades it
As of Nov 16, 2026, RXRX insiders reported 35 open-market sales worth $7.6M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Blake Borgeson (Director), with $4.5M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Recursion Pharmaceuticals
From the latest filingsOverall: more buying than selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RXRX
341 funds and institutions reported RXRX shares worth $1.3B at the end of Q2 2026, about 68% of the company. The largest holder is BlackRock, Inc. with 9.4%.
Funds and institutions (13F) 68%Everyone else 32%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 50.30M | 9.40% | $185M | +16% |
| ARK Investment Management LLC | 41.34M | 7.72% | $152M | +3% |
| State Street Corp | 34.71M | 6.48% | $127M | +22% |
| Vanguard Portfolio Management LLC | 31.13M | 5.82% | $114M | +37% |
| Baillie Gifford & Co | 23.49M | 4.39% | $86.2M | -1% |
| Vanguard Capital Management LLC | 22.77M | 4.25% | $83.6M | +2% |
| Geode Capital Management, LLC | 13.82M | 2.58% | $50.7M | +13% |
| Softbank Group Corp. | 13.64M | 2.55% | $50M | No change |
| MIC Capital Management UK LLP | 9.64M | 1.80% | $35.4M | No change |
| UBS Group AG | 8.95M | 1.67% | $32.8M | +75% |
| Norges Bank | 6.83M | 1.28% | $25.1M | – |
| Data Collective IV GP, LLC | 5.94M | 1.11% | $21.8M | No change |
| Amova Asset Management Americas, Inc. | 5.51M | 1.03% | $20.2M | +2% |
| Sumitomo Mitsui Trust Group, Inc. | 5.51M | 1.03% | $20.2M | +2% |
| Northern Trust Corp | 4.76M | 0.89% | $17.5M | +20% |
| Marshall Wace, LLP | 4.71M | 0.88% | $17.3M | +64% |
| Charles Schwab Investment Management Inc | 4.14M | 0.77% | $15.2M | +9% |
| Sixth Street Partners Management Company, L.P. | 4.14M | 0.77% | $15.2M | – |
| DCVC Opportunity Fund II GP, LLC | 3.95M | 0.74% | $14.5M | No change |
| Goldman Sachs Group Inc | 3.92M | 0.73% | $14.4M | -35% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RXRX insiders reported $0 of open-market purchases and $7.6M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Blake Borgeson | Director | Sale plan | 40,000 | $3.88 | $155K | Form 4 |
| Oct 6, 2026 | Blake Borgeson | Director | Sale plan | 50,000 | $4.84 | $242K | Form 4 |
| Oct 6, 2026 | Robert Hershberg | Director | Sale plan | 25,000 | $5.00 | $125K | Form 4 |
| Sep 8, 2026 | Najat Khan | CEO | Sale plan | 22,408 | $3.52 | $78.9K | Form 4 |
| Sep 1, 2026 | Blake Borgeson | Director | Sale plan | 30,000 | $3.34 | $100K | Form 4 |
| Aug 4, 2026 | Blake Borgeson | Director | Sale plan | 30,000 | $3.25 | $97.5K | Form 4 |
| Jul 7, 2026 | Blake Borgeson | Director | Sale plan | 40,000 | $3.96 | $158K | Form 4 |
| Jun 18, 2026 | Namandje Bumpus | Director | Sale plan | 3,963 | $3.18 | $12.6K | Form 4 |
| Jun 5, 2026 | Christopher Gibson | Director | Sale plan | 40,000 | $3.62 | $145K | Form 4 |
| Jun 5, 2026 | Najat Khan | CEO | Sale plan | 23,588 | $3.58 | $84.4K | Form 4 |
| Jun 3, 2026 | Namandje Bumpus | Director | Sale plan | 4,386 | $3.54 | $15.5K | Form 4 |
| Jun 2, 2026 | Blake Borgeson | Director | Sale plan | 30,000 | $3.68 | $110K | Form 4 |
| May 22, 2026 | Christopher Gibson | Director | Sale plan | 40,000 | $3.08 | $123K | Form 4 |
| May 7, 2026 | Christopher Gibson | Director | Sale plan | 40,000 | $3.37 | $135K | Form 4 |
| May 5, 2026 | Blake Borgeson | Director | Sale plan | 30,000 | $3.52 | $106K | Form 4 |
| Apr 22, 2026 | Christopher Gibson | Director | Sale plan | 40,000 | $3.61 | $144K | Form 4 |
| Apr 7, 2026 | Christopher Gibson | Director | Sale plan | 40,000 | $3.10 | $124K | Form 4 |
| Apr 7, 2026 | Blake Borgeson | Director | Sale plan | 30,000 | $3.10 | $93K | Form 4 |
| Mar 23, 2026 | Christopher Gibson | Director | Sale plan | 40,000 | $3.25 | $130K | Form 4 |
| Mar 17, 2026 | Ben R Taylor | CFO | Sale plan | 7,956 | $3.39 | $27K | Form 4 |
| Mar 9, 2026 | Najat Khan | CEO | Sale plan | 28,298 | $3.35 | $94.8K | Form 4 |
| Mar 3, 2026 | Blake Borgeson | Director | Sale plan | 170,000 | $3.46 | $588K | Form 4 |
| Feb 19, 2026 | Christopher Gibson | Director | Sale plan | 40,000 | $3.46 | $138K | Form 4 |
| Feb 18, 2026 | Ben R Taylor | CFO | Sale plan | 13,426 | $3.08 | $41.4K | Form 4 |
| Feb 4, 2026 | Christopher Gibson | Director | Sale plan | 40,000 | $4.12 | $165K | Form 4 |
| Feb 3, 2026 | Blake Borgeson | Director | Sale plan | 220,000 | $4.20 | $924K | Form 4 |
| Jan 20, 2026 | Christopher Gibson | Director | Sale plan | 40,000 | $4.47 | $179K | Form 4 |
| Jan 6, 2026 | Blake Borgeson | Director | Sale plan | 220,000 | $4.36 | $959K | Form 4 |
| Jan 5, 2026 | Christopher Gibson | Director | Sale plan | 40,000 | $4.25 | $170K | Form 4 |
| Dec 29, 2025 | Ben R Taylor | CFO | Sale plan | 21,383 | $4.18 | $89.4K | Form 4 |
| Dec 22, 2025 | Najat Khan | Director | Sale plan | 124,403 | $4.41 | $549K | Form 4 |
| Dec 19, 2025 | Christopher Gibson | CEO | Sale plan | 40,000 | $4.50 | $180K | Form 4 |
| Dec 4, 2025 | Christopher Gibson | CEO | Sale plan | 40,000 | $4.63 | $185K | Form 4 |
| Dec 2, 2025 | Blake Borgeson | Director | Sale plan | 220,000 | $4.37 | $961K | Form 4 |
| Nov 19, 2025 | Christopher Gibson | CEO | Sale plan | 40,000 | $4.16 | $166K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Blake Borgeson | Director | – | $4.5M | Nov 3, 2026 |
| Christopher Gibson | Chief Executive Officer, Director | – | $2M | Jun 5, 2026 |
| Najat Khan | Chief R&D Commercial Officer, Director | – | $807K | Sep 8, 2026 |
| Ben R Taylor | Chief Financial Officer | – | $158K | Mar 17, 2026 |
| Robert Hershberg | Director | – | $125K | Oct 6, 2026 |
| Namandje Bumpus | Director | – | $28.1K | Jun 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RXRX short interest
Very high short interest. 22.8% of RXRX shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went down 23%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 142.27M RXRX shares were sold short, 22.8% of the shares outstanding, down 12.1% from the report before. At the average daily volume of 23.33M shares, buying them all back would take about 6.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 142.27M | 22.84% | -12% | 23.33M | 6.1 |
| Oct 15, 2026 | 161.93M | 30.25% | +3% | 36.46M | 4.4 |
| Sep 30, 2026 | 157.94M | 29.50% | -12% | 25.77M | 6.1 |
| Sep 15, 2026 | 178.72M | 33.39% | -0% | 14.22M | 12.6 |
| Aug 31, 2026 | 179.15M | 33.46% | +1% | 16.90M | 10.6 |
| Aug 14, 2026 | 177.92M | 33.24% | -2% | 13.31M | 13.4 |
| Jul 31, 2026 | 180.77M | 33.77% | No change | 19.41M | 9.3 |
| Jul 15, 2026 | 180.76M | – | +5% | 26.88M | 6.7 |
| Jun 30, 2026 | 172.30M | – | -6% | 20.55M | 8.4 |
| Jun 15, 2026 | 184.02M | – | +12% | 22.01M | 8.4 |
| May 29, 2026 | 164.34M | – | -11% | 20.50M | 8.0 |
| May 15, 2026 | 184.44M | – | +8% | 13.89M | 13.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Recursion Pharmaceuticals company events
Recursion Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 2, 2026.
- Nov 2, 2026LeadershipThe Board of Directors of the Company, upon the recommendation from its Nominating and Corporate Governance Committee, increased the number of members of the Board from 9 to 10 and appointed Fred Hassan as Chair of the Board, effective immediately. Filing
- Oct 15, 2026AgreementRecursion Pharmaceuticals, Inc. entered into an underwriting agreement with Leerink Partners LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein, relating to the offering of 61,540,000 shares of its Class A… Filing
- Sep 21, 2026AgreementRecursion Pharmaceuticals, Inc. and Tempus AI, Inc., acknowledging the value of (i) Tempus’s library of multimodal data and (ii) Recursion’s proprietary foundational RNA sequencing model, have entered into the following agreements: Amendment to Tempus Master Agreement On September 15, 2026, the… Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Apr 30, 2026LeadershipChristopher Gibson, Ph.D., Chair of the Board of Directors of Recursion Pharmaceuticals, Inc. and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will not stand for re-election to… Filing
- Mar 25, 2026LeadershipRecursion Pharmaceuticals, Inc. announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026, as David Mauro, M.D., Ph.D. transitions out of the role. Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Dec 8, 2025AnnouncementRecursion Pharmaceuticals, Inc. issued a press release announcing Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP). Filing
- Nov 26, 2025AnnouncementRecursion Pharmaceuticals, Inc. filed a prospectus supplement dated November 26, 2025 and an accompanying base prospectus, which are part of Recursion’s automatic “shelf” Registration Statement on Form S-3ASR (File No. 333-284878), which was previously filed on February 12, 2025 with the Securities… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Recursion Pharmaceuticals financials
Famous investors that hold RXRX
5 of the 50 well-known investors we track reported holding RXRX in their latest 13F filing. The largest position is Cathie Wood's, worth $185M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Cathie Wood · ARK Investment Management | Q3 2026 | 44.75M | $185M | 1.1% | +8% |
| Israel Englander · Millennium Management | Q3 2026 | 4.04M | $16.7M | 0.0% | +120% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.96M | $12.2M | 0.0% | +2206% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 238,435 | $985K | 0.0% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 96,596 | $399K | 0.0% | +156% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named RXRX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | ARK Investment Management LLC | 13G/A | 8.4% |
| Nov 13, 2026 | ARK Investment Management LLC | 13G/A | 8.4% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.6% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.6% |
Questions about Recursion Pharmaceuticals, Inc. (RXRX) stock
Who owns the most RXRX stock?
The largest reported owner of Recursion Pharmaceuticals, Inc. (RXRX) is BlackRock, Inc., with 9.4% of the company. In total, 341 funds and institutions reported holding RXRX at the end of Q2 2026, together about 68% of the shares. See the largest owners.
Are RXRX insiders buying or selling?
In the last 12 months, RXRX insiders reported no open-market purchases and 35 sales worth $7.6M. The latest trade was on Nov 3, 2026. See every trade.
What is the short interest in RXRX?
As of Oct 30, 2026, 142.27M RXRX shares were sold short, 22.8% of the shares outstanding, down 12.1% from the report before. At the average daily volume of 23.33M shares, buying them all back would take about 6.1 trading days (days to cover). See the history.
Which famous investors hold RXRX?
5 of the 50 well-known investors we track reported RXRX in their latest 13F filing, including Cathie Wood, Israel Englander, Ken Griffin. The largest position is worth $185M. See all holders.
Executive pay
Recursion Pharmaceuticals's chief executive was paid a total of $9.6M for the year ended Dec 31, 2025, up 13% from $8.5M the year before. In the last 12 months, Recursion Pharmaceuticals's executives and directors bought no stock on the open market and sold $7.6M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.